Indaptus Therapeutics (NASDAQ:INDP) Trading 5.2% Higher – Here’s Why

Indaptus Therapeutics, Inc. (NASDAQ:INDP)’s stock price rose 5.2% during mid-day trading on Friday . The stock traded as high as $1.2350 and last traded at $1.22. Approximately 133,112 shares traded hands during mid-day trading, a decline of 85% from the average daily volume of 876,766 shares. The stock had previously closed at $1.16.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Wall Street Zen upgraded Indaptus Therapeutics to a “hold” rating in a report on Saturday, June 27th. Weiss Ratings restated a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Indaptus Therapeutics Price Performance

The company’s 50 day simple moving average is $1.83 and its 200 day simple moving average is $2.12. The stock has a market cap of $162.55 million, a P/E ratio of -0.19 and a beta of 1.17.

Indaptus Therapeutics (NASDAQ:INDP) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.57) by $1.55.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC bought a new stake in Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 7.06% of the company’s stock.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.